Pharma Focus Asia

Repligen

LATEST NEWSRead more...

19

Jun 2024

Junshi Biosciences Gains Approval for sNDA of Toripalimab as First-Line Therapy for Small Cell Lung Cancer

Shanghai Junshi Biosciences Co Ltd a leading biopharmaceutical company focused on developing innovative therapies announced that the National Medical Products

19

Jun 2024

Ionis and Otsuka Expand Licensing Agreement for Hereditary Angioedema Drug Donidalorsen in Asia Pacific

Ionis Pharmaceuticals Inc has finalized a licensing agreement with Otsuka Pharmaceutical Co Ltd granting Otsuka exclusive rights to donidalorsen in the AsiaPacific region

19

Jun 2024

Spyre Therapeutics Initiates Phase 1 Study of SPY001, a Novel Antibody Targeting α4β7 for Inflammatory Bowel Disease Therapy

Spyre Therapeutics Inc a biotechnology firm focused on the development of innovative treatments for Inflammatory Bowel Disease has announced the initiation of its first clinical trial

18

Jun 2024

Northwest Biotherapeutics Acquires Exclusive Rights to Dendritic Cell Technology Suite

Northwest Biotherapeutics a biotechnology company focused on DCVax personalized immune therapies for solid tumor cancers announced on June that it has acquired

18

Jun 2024

FDA Approves Phase II Study of Ruxoprubart for ANCA-Associated Vasculitis

NovelMed is pleased to announce that Ruxoprubart an experimental drug has received approval from the US Food and Drug Administration FDA to initiate a clinical trial focused on patients with ANCA Associated Vasculitis AAV is a rare autoimmune disorder that leads to chronic inflammation in small

18

Jun 2024

ReviR Therapeutics and Asieris Pharmaceuticals Reach Milestone in RNA-Targeted Cancer Therapy Development

ReviR Therapeutics a biotechnology firm focused on creating small molecule RNA splicing modulators for neurogenetic diseases and cancer and Asieris Pharmaceuticals a global leader in developing

Solovpe

press releasesRead more...

19

Jun 2024

YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China

YolTech a clinicalstage biopharmaceutical company specializing in mRNALNP delivery for in vivo gene editing therapies has partnered with KACTUS a leading developer serving the biopharmaceutical industry

19

Jun 2024

Menarini Asia-Pacific partners with Pharmacosmos to expand its reach of MonoFer® to Singapore and Malaysia

Menarini AsiaPacific today announced that it has expanded its partnership with Pharmacosmos AS to include exclusive rights to commercialise MonoFer

19

Jun 2024

Singleron Biotechnologies partners with the Human Cell Atlas (HCA) to enhance access to single cell analysis globally

Singleron Biotechnologies announced a partnership with the Human Cell Atlas to help accelerate the adoption of single cell sequencing globally Singleron will facilitate access

19

Jun 2024

Ability Biologics Announces Closing of US$18 Million Seed Funding to Generate Novel, Highly Targeted Immunomodulators

Ability Biologics announced the closing of its US million seed round a financing round led by Amplitude Ventures an investor founder of Ability The Fonds de solidarit FTQ Investissement Qubec

18

Jun 2024

Zuellig Pharma launches innovative B2B e-commerce healthcare purchasing platform, eZRx+, to better serve pharmacies and clinics in Asia

Zuellig Pharma a leading healthcare solutions company in Asia has announced that it has launched eZRx an enhanced version of its premier selfservice BB eCommerce healthcare purchasing platform

18

Jun 2024

Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Trial of MTX-101, in Development for Treatment of Autoimmune Diseases

Mozart Therapeutics a clinical stage biopharmaceutical company focused on the development of CD Treg modulators in autoimmune diseases today announce the dosing of the first cohort of participants

18 - 19

Jun 2024

18 - 20

Jun 2024

5th RNA Editing Summit

Boston, MA, USA

18 - 19

Jun 2024

19 - 20

Jun 2024

LogiPharma Asia 2024

Equarius Hotel, Singapore

19 - 21

Jun 2024

CPHI & PMEC 2024

Shanghai, China

20 - 22

Jun 2024

20 - 22

Jun 2024
magazine-slider-image
Cytiva - Supor Prime filters
MFA + MMA 2024
CPHI China || PMEC China 2024
Asia Healthcare Week 2024
CPHI Korea 2024
World Orphan Drug Congress Europe 2024
Thermo Fisher - Drug Discovery and the impact of mAbs

TOP ARTICLES

  • 1

    Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery

    Dr. Stevan Pecic

    Department of Chemistry and Biochemistry, California State University, Fullerton, USA.

    Xiaohui Weng

    Department of Chemistry and Biochemistry, California State University, Fullerton, USA.

    Michael Gonzalez

    Department of Chemistry and Biochemistry, California State University, Fullerton, USA.

    Arya Emami

    Faculty of Dentistry, University of Toronto, Toronto, Canada.

    Dr. Amir Barzegar Behrooz

    College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipewg, Manitoba, Canada.

    Dr. Rui Vitorino

    Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal.

    Dr. Saeid Ghavami

    Research Institute of Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, Canada.

  • 4

    Analysis of Blood Microbiota Compositionin Cardiovascular Disease Patients

    Ikram Khan

    School of Life Sciences, Lanzhou University, Gansu Province, China

    Imran Khan

    Department of Microbiology, Khyber Medical University Peshawar, Pakistan

    Zhou Jianye

    School of Stomatology, Northwest Minzu University, Lanzhou, Gansu, China

    Xie Ping

    Gansu Public Provincial Hospital, Gansu Province, China

    Li Zhiqiang

    Department of Microbiology, Khyber Medical University Peshawar, Pakistan

    An Lizhe

    School of Life Sciences, Lanzhou University, Gansu Province, China

    Zhang Xiaowei

    Lanzhou University Second Hospital, Gansu Province, China

KNOWLEDGE BANK

  • Interviews

    Interpharm Consultancy

    Founder

    Interpharm Consultancy has been providing advice about the UK generic market and consultancy services to generic manufacturers and distributors
  • Articles

    Artificial Intelligence in Oncology

    Cancer is the most prevalent cause of death across the globe According to the World Health Organization there is an estimated increase from the anticipated million cases of cancer in It is predicted that more than million

  • White Papers

    Supplier Diversity in Pharmaceutical R&D

    Procurement decisions are no longer limited to cost savings quality and time sustainability is the new addition to procurement decision making Risks arising from environmental and social factors compliance value creation and external demand are driving sustainable procurement Supplier Diversity an aspect that impacts the sustainability of procurement has gained much importance today This whitepape...

EDITORIAL SECTION